Cell stress-mediated changes in the Herpes simplex virus type 1 chromatin structure during reactivation from latent infection
单纯疱疹病毒1型染色质结构在潜伏感染重新激活过程中细胞应激介导的变化
基本信息
- 批准号:10357923
- 负责人:
- 金额:$ 35.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-03-15 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:ATRX geneAntiviral AgentsBinding ProteinsCellular StressChIP-seqChromatinChromatin StructureComplexCorneaDNADNA BindingDNA SequenceDataDiseaseEncephalitisEpigenetic ProcessEventExcisionExhibitsFatality rateGene ExpressionGenitalGenitaliaGenomeGoalsHerpes encephalitisHerpesvirus 1HeterochromatinHeterogeneityHistone H3HistonesImmune responseImmunofluorescence ImmunologicInfectionInflammationJUN geneKeratitisLesionLifeLightLinkLysineLyticMAPK8 geneMediatingMediator of activation proteinModelingModificationMolecularMorbidity - disease rateN-terminalNeuraxisNeuronsOral cavityPathway interactionsPeptidesPeripheralPharmaceutical PreparationsPhosphorylationPhosphotransferasesProcessProteinsRecurrenceRoleSerineSignal TransductionSimplexvirusSiteStressSurvivorsSystemTestingTranscriptional ActivationUp-RegulationVaccinesViralViral Gene Expression RegulationViral GenesViral GenomeVirusVirus ActivationVirus Latencybiological adaptation to stressdemethylationgene inductionhistone demethylasein vitro Modelin vivo Modelinsightknock-downlatent infectionlong-term sequelaelytic gene expressionmortalitymouse modelnovelpreventpromoterreactivation from latencyrecruitresponsesmall hairpin RNAtargeted treatmenttherapy developmenttransmission process
项目摘要
Project Summary/abstract
Herpes simplex virus (HSV) persists for life in peripheral neurons in the form of a latent infection. In response
to neuronal stress, the virus reactivates from latency to permit reinfection. Reactivation is associated with
significant disease. For example, replication in the cornea following reactivation results in keratitis.
Transmission to the central nervous system following reactivation can result in herpes simplex encephalitis
(HSE). Without treatment, HSE has a fatality rate of 70%, and even with treatment, many survivors exhibit
long-term sequelae. Although anti-viral drugs are available that limit HSV productive replication, no therapies
target the latent stage of infection to prevent reactivation and there is no vaccine against HSV. Therefore, our
long-term goals are to understand how HSV responds to neuronal stress and develop strategies to prevent
reactivation occurring. Our lab and others have shown that the mechanism by which viral gene expression
initiates during reactivation is distinct from de novo infection with the virus. We have found that a neuronal
stress pathway resulting in activation of c-Jun N-terminal kinase (JNK) triggers changes to the viral chromatin
and permits reactivation. Specifically, the histones associated with viral promoters maintained a modification
associated with heterochromatin (H3K9me3) but also became phosphorylated on H3S10 in a JNK-dependent
manner. Using both a primary neuronal model of HSV-1 latency that we have developed and mouse models of
infection we will determine how activation of JNK permits viral gene expression to be induced during
reactivation. By performing ChIP-seq and shRNA knock-down of candidate proteins, we will examine how JNK
gets recruited to viral promoters and identify additional cellular proteins involved in HSV-1 reactivation. We will
also determine how JNK signaling overcomes the H3K27me3 repressive histone medication to permit
reactivation from genomes associated with this modification. Finally, we will examine the mechanism that
ATRX restricts HSV-1 reactivation and test the hypothesis that genomes associated with ATRX are non-
permissive for reactivation. These studies into the intimate interaction between the latent viral genome and
initiation of a neuronal stress response are especially significant as they provide mechanistic insight into how
the virus undergoes reactivation. Because the virus has likely co-opted cellular pathway to achieve
reactivation, we will also uncover process that are important for the host response to neuronal stress.
Importantly, by understanding the very earliest events in HSV reactivation, our long-term goals are to develop
therapies that target the latent genome and make it unresponsive for reactivation.
项目总结/文摘
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Strength in diversity: Understanding the pathways to herpes simplex virus reactivation.
- DOI:10.1016/j.virol.2018.07.011
- 发表时间:2018-09
- 期刊:
- 影响因子:3.7
- 作者:Suzich JB;Cliffe AR
- 通讯作者:Cliffe AR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Ruth Cliffe其他文献
Anna Ruth Cliffe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anna Ruth Cliffe', 18)}}的其他基金
Investigating the role of long-term latent herpes simplex virus infection on APOE4-associated Alzheimer's disease pathogenesis
研究长期潜伏的单纯疱疹病毒感染对 APOE4 相关阿尔茨海默病发病机制的作用
- 批准号:
10740641 - 财政年份:2023
- 资助金额:
$ 35.02万 - 项目类别:
Cell stress-mediated changes in the Herpes simplex virus type 1 chromatin structure during reactivation from latent infection
单纯疱疹病毒1型染色质结构在潜伏感染重新激活过程中细胞应激介导的变化
- 批准号:
10112968 - 财政年份:2018
- 资助金额:
$ 35.02万 - 项目类别:
Intersection of HSV latency and reactivation with the neuronal apoptotic pathway
HSV 潜伏期和再激活与神经元凋亡途径的交叉点
- 批准号:
8432969 - 财政年份:2012
- 资助金额:
$ 35.02万 - 项目类别:
Intersection of HSV latency and reactivation with the neuronal apoptotic pathway
HSV 潜伏期和再激活与神经元凋亡途径的交叉点
- 批准号:
8628197 - 财政年份:2012
- 资助金额:
$ 35.02万 - 项目类别:
Intersection of HSV latency and reactivation with the neuronal apoptotic pathway
HSV 潜伏期和再激活与神经元凋亡途径的交叉点
- 批准号:
8316708 - 财政年份:2012
- 资助金额:
$ 35.02万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 35.02万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 35.02万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 35.02万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 35.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 35.02万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 35.02万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 35.02万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 35.02万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 35.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 35.02万 - 项目类别:














{{item.name}}会员




